2
Clinical Trials associated with rF1V-1018 Vaccine(Dynavax Technologies)Phase 2, Randomized, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
This study will evaluate the immunogenicity, safety, and tolerability of rF1V-1018 vaccine
Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018? Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine with CpG 1018? Adjuvant Compared with rF1V Vaccine in Adults 18 to 55 Years of Age
100 Clinical Results associated with rF1V-1018 Vaccine(Dynavax Technologies)
100 Translational Medicine associated with rF1V-1018 Vaccine(Dynavax Technologies)
100 Patents (Medical) associated with rF1V-1018 Vaccine(Dynavax Technologies)
100 Deals associated with rF1V-1018 Vaccine(Dynavax Technologies)